{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:21:59Z","timestamp":1777522919790,"version":"3.51.4"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Podoplanin is one of the integral molecules controlling cellular motility and migration that is considered crucial in initiating tumor invasiveness and metastasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>This work aimed at studying the immunohistochemical expression of podoplanin in nonmelanoma skin cancers (NMSCs) and seborrheic keratosis (SK) in comparison to normal control skin and to evaluate its possible role in their pathogenesis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>This study included 120 patients and paraffin blocks of epidermal tumors [30 SK, 30 basal cell carcinoma (BCC), 30 basosquamous carcinoma (BSC) and 30 squamous cell carcinoma (SCC)], in addition to 30 normal control skin specimens from age- and sex-matched healthy volunteers. All were examined for intratumoral and peritumoral immunohistochemical expression of podoplanin antibody (D2-40). In addition, morphometric measurement of lymphatic vessel density was evaluated in all studied specimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Podoplanin expression was significantly upregulated in all the studied epidermal tumor specimens in comparison to normal control skin specimens. The highest mean value of podoplanin expression (both intratumoral and peritumoral cells) was observed in SCC followed by BSC, then BCC, SK, and control skin in the same sequence. Positive correlations were detected between its expression in both BSC and SCC with the mean of lymphatic vessel density in the studied specimens and the presence of lymph node metastasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Podoplanin plays an evident role in the development and progression of both benign and malignant skin neoplasms and may serve as a potential predictor of their clinical course and prognosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dad.0000000000001561","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T20:38:19Z","timestamp":1572899899000},"page":"432-438","source":"Crossref","is-referenced-by-count":11,"title":["The Prognostic Value of Podoplanin Expression in Nonmelanoma Skin Cancers: Correlation With Lymphatic Vessel Density"],"prefix":"10.1097","volume":"42","author":[{"given":"Yomna Mazid El-Hamd","family":"Neinaa","sequence":"first","affiliation":[{"name":"Dermatology and Venereology Department, Faculty of Medicine, Tanta University, Tanta, Egypt;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal Ahmad","family":"El-Ashmawy","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology Department, Faculty of Medicine, Tanta University, Tanta, Egypt;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan Al-Saeid","family":"Alshenawy","sequence":"additional","affiliation":[{"name":"Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wesam Lotfy","family":"Dorgham","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology Department, El-Behaira General Hospital, El-Behaira, Egypt."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"key":"R1-20230908","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000479529","article-title":"Neoplastic multifocal skin lesions: biology, etiology, and targeted therapies for non-melanoma skin cancers","volume":"31","author":"Fernandes","year":"2018","journal-title":"Skin Pharmacol Physiol."},{"key":"R2-20230908","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/biomedicines6010006","article-title":"Non melanoma skin cancer pathogenesis overview","volume":"6","author":"Didona","year":"2018","journal-title":"Biomedicines."},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/ijd.12587","article-title":"Basosquamous carcinoma and metatypical basal cell carcinoma: a review of treatment with Mohs micrographic surgery","volume":"53","author":"Allen","year":"2014","journal-title":"Int J Dermatol."},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1067\/mjd.2000.107497","article-title":"The nature of solar keratosis: a critical review in historical perspective","volume":"43","author":"Heaphy","year":"2000","journal-title":"J Am Acad Dermatol."},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"E707","DOI":"10.3390\/ijms20030707","article-title":"Podoplanin in inflammation and cancer","volume":"20","author":"Quintanilla","year":"2019","journal-title":"Int J Mol Sci."},{"key":"R6-20230908","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fimmu.2012.00283","article-title":"Podoplanin: emerging functions in development, the immune system, and cancer","volume":"3","author":"Astarita","year":"2012","journal-title":"Front Immunol."},{"key":"R7-20230908","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10555-017-9672-2","article-title":"Platelet-activating factor podoplanin: from discovery to drug development","volume":"36","author":"Takemoto","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"R8-20230908","first-page":"2997","article-title":"The role of podoplanin in tumor progression and metastasis","volume":"28","author":"Raica","year":"2008","journal-title":"Anticancer Res."},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/cas.13580","article-title":"Podoplanin: an emerging cancer biomarker and therapeutic target","volume":"109","author":"Krishnan","year":"2018","journal-title":"Cancer Sci."},{"key":"R10-20230908","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jaad.2010.08.033","article-title":"A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics","volume":"64","author":"Farasat","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"R11-20230908","first-page":"1591","article-title":"Expression of podoplanin in non-melanoma skin cancers and actinic keratosis","volume":"36","author":"Zdrojowy","year":"2016","journal-title":"Anticancer Res."},{"key":"R12-20230908","doi-asserted-by":"crossref","first-page":"798","DOI":"10.4103\/0973-1482.146123","article-title":"Lymphatic vessel assessment by podoplanin (D2-40) immunohistochemistry in breast cancer","volume":"11","author":"Wahal","year":"2015","journal-title":"J Cancer Res Ther."},{"key":"R13-20230908","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0002-9440(10)62311-5","article-title":"Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors","volume":"166","author":"Schacht","year":"2005","journal-title":"Am J Pathol."},{"key":"R14-20230908","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/jso.23238","article-title":"Podoplanin expression in cutaneous head and neck squamous cell carcinoma\u2014prognostic value and clinicopathologic implications","volume":"107","author":"Kreppel","year":"2013","journal-title":"J Surg Oncol."},{"key":"R15-20230908","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1159\/000450920","article-title":"Characterization of prognosis and invasion of cutaneous squamous cell carcinoma by podoplanin and E-cadherin expression","volume":"232","author":"Hesse","year":"2016","journal-title":"Dermatology."},{"key":"R16-20230908","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/cup.12859","article-title":"The expression of podoplanin is associated with poor outcome in cutaneous squamous cell carcinoma","volume":"44","author":"Ca\u00f1ueto","year":"2017","journal-title":"J Cutan Pathol."},{"key":"R17-20230908","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jdermsci.2011.11.011","article-title":"Podoplanin expression in wound and hyperproliferative psoriatic epidermis: regulation by TGF-\u03b2 and STAT- 3 activating cytokines, IFN-\u03b3, IL- 6, and IL-22","volume":"65","author":"Honma","year":"2012","journal-title":"J Dermatol Sci."},{"key":"R18-20230908","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/omcr\/omw095","article-title":"Basosquamous carcinoma: appearance and reality","volume":"2017","author":"Anand","year":"2017","journal-title":"Oxf Med Case Rep."},{"key":"R19-20230908","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/PAI.0b013e31824bb3ea","article-title":"Lymphangiogenesis and podoplanin expression in oral squamous cell carcinoma and the associated lymph nodes","volume":"20","author":"de Sousa","year":"2012","journal-title":"Appl Immunohistochem Mol Morphol."},{"key":"R20-20230908","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/jomfp.JOMFP_272_17","article-title":"An immunohistochemical evaluation of podoplanin expression in oral leukoplakia and oral squamous cell carcinoma to explore its potential to be used as a predictor for malignant transformation","volume":"23","author":"Aiswarya","year":"2019","journal-title":"J Oral Maxillofac Pathol."},{"key":"R21-20230908","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3892\/or.2015.4070","article-title":"Podoplanin is involved in the prognosis of head and neck squamous cell carcinoma through interaction with VEGF-C","volume":"34","author":"Kim","year":"2015","journal-title":"Oncol Rep."},{"key":"R22-20230908","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.21873\/anticanres.12968","article-title":"Lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma","volume":"38","author":"Arimoto","year":"2018","journal-title":"Anticancer Res."},{"key":"R23-20230908","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4103\/0019-509X.178427","article-title":"Role of podoplanin in potentially malignant disorders and oral squamous cell carcinoma and its correlation with lymphangiogenesis","volume":"52","author":"Parhar","year":"2015","journal-title":"Indian J Cancer."},{"key":"R24-20230908","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1242\/jcs.03218","article-title":"Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition","volume":"119","author":"Mart\u00edn-Villar","year":"2006","journal-title":"J Cell Sci."},{"key":"R25-20230908","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.yexcr.2009.02.021","article-title":"Galectin-8 interacts with podoplanin and modulates lymphatic endothelial cell functions","volume":"315","author":"Cueni","year":"2009","journal-title":"Exp Cell Res."},{"key":"R26-20230908","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1091\/mbc.e10-06-0489","article-title":"Podoplanin associates with CD44 to promote directional cell migration","volume":"21","author":"Mart\u00edn-Villar","year":"2010","journal-title":"Mol Biol Cell."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000001561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:14:54Z","timestamp":1694150094000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000001561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000001561","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,29]]}}}